Life Science Investing Profound Medical Corp. Closes $36 Million Registered Direct Offering; Expects to Complete Subsequent Private Placement On or Before December 30th
Life Science Investing Profound Medical Corp. Announces Pricing of up to $40 Million Financing Comprised of a $36 Million Registered Direct Offering and a Subsequent $4 Million Private Placement
Life Science Investing Stanford Medicine's Dr. Pejman Ghanouni Receives RSNA's Cum Laude Award for CAPTAIN Perioperative Data Presentation
Life Science Investing Profound Medical to Launch AI-Powered BPH Module, Present New TULSA-PRO® Clinical Data, at RSNA and SUO Meetings
Life Science Investing Profound Medical Celebrates The Hong Center's 200th Independent TULSA Procedure for Prostate Disease
Life Science Investing Profound Medical Announces Strategic Distribution Agreement with Getz Healthcare to Bring TULSA-PRO® to Australia and New Zealand
Life Science Investing Profound Medical Inks Exclusive Distribution Agreement for TULSA-PRO® and Sonalleve® with Al Faisaliah Medical Systems in Saudi Arabia
Life Science Investing Profound Medical Regains Exclusive Distribution Rights for TULSA-PRO® in Canada from Knight
Life Science Investing Profound Medical Congratulates the Busch Center for Achieving 500th TULSA Procedure Milestone
Life Science Investing Profound Medical Achieves Record Preliminary Unaudited Revenue for the 2025 Third Quarter
SAGA Metals Highlights Radar Titanium Opportunity as North America Confronts Defense Driven Titanium Supply Chain Risks
RETRANSMISSION: Blackrock Silver Closes C$15 Million Private Placement Led By a C$7 Million Investment from Eric Sprott
